Addendum

Secukinumab (plaque psoriasis in children and adolescents) - Addendum to Commission A20-78

Report documents

Indication:

Children and adolescents from the age of 6 years with moderate to severe plaque psoriasis who are candidates for systemic therapy.

Result of dossier assessment:

Added benefit still not proven

2021-02-18: A G-BA decision was published.

Project no.: A21-02
Commission: Commission awarded on 12.01.2021 by the Federal Joint Committee (GBA).
Report type: Addendum
Status: Commission completed
Department/Division: Drug Assessment
Topic: Skin and hair
Note: If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.